The battle against breast cancer is far from over, and a new research initiative called BRIDGE is stepping into the fray with a bold mission: to turn the tide against aggressive breast cancer by understanding how it turns off the immune system. This project, a collaboration between the Instituto de Tecnologia Química e Biológica António Xavier of NOVA University of Lisbon (ITQB NOVA) and the Portuguese Institute of Oncology (IPOFG), aims to unlock the secrets of tumor-immune communication, potentially leading to more personalized and effective treatments.
Unveiling the Tumor Microenvironment
The focus is on the tumor microenvironment, a complex ecosystem comprising cancer cells, immune cells, blood vessels, and supporting structures. Within this environment, small molecules on cell surfaces take center stage. These molecules, the researchers hypothesize, play a crucial role in enabling tumors to evade immune detection, allowing them to grow unchecked.
Catarina Brito, leader of the Advanced Cell Models laboratory at ITQB NOVA, explains, "We have previously identified how tumors communicate with certain cells of the immune system to protect themselves. With BRIDGE, we aim to validate these findings using real patient samples and translate this knowledge into clinical applications."
The Power of Patient Samples
The IPOFG will provide patient samples, a vital step in confirming the validity of laboratory discoveries in real-world clinical settings. This process is essential for bridging the gap between scientific research and practical medical tools.
Brito emphasizes, "By finding new biomarkers, we hope to contribute to more precise therapies."
Personalized Breast Cancer Care
The ultimate goal of BRIDGE is to revolutionize breast cancer treatment by deepening our understanding of tumor-immune interactions. This knowledge will enable the identification of biomarkers for disease tracking and the development of novel therapeutic targets, potentially leading to more effective and personalized treatments.
In the long run, this initiative could pave the way for a paradigm shift in breast cancer care, moving away from a one-size-fits-all approach towards tailored treatments specific to each patient's cancer characteristics.
Funding and Future Prospects
The BRIDGE project is supported by the iNOVA4Health Lighthouse Projects (LHP) 2025 program, which funds research with strong potential for clinical translation. With up to €75,000 in funding over the next two years, the project is poised to accelerate the development of new strategies for understanding, monitoring, and treating aggressive breast cancer.
As BRIDGE delves deeper into the mysteries of tumor-immune communication, it holds the promise of not only improving breast cancer treatment but also advancing our understanding of cancer biology, ultimately contributing to a more personalized and effective approach to this devastating disease.
